Pneumococcal vaccine - ImmunoBiology
Alternative Names: PnuBioVax™Latest Information Update: 30 Oct 2021
At a glance
- Originator ImmunoBiology
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Pneumococcal infections
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Pneumococcal-infections(In volunteers) in United Kingdom (IM, Injection)
- 25 Mar 2019 PnuBioVax is still in phase I trial for Pneumococcal infections(In volunteers) in United Kingdom (IM, Injection)
- 18 Mar 2019 ImmunoBiology enters into a licensing agreement with China National Biotec Group (CNBG) to co-develop PnuBioVax vaccine against Pneumococcal infections in Greater China